Despite the promising preclinical data on the inhibitory effect of afatinib in specific KRAS-mutated CRC cell lines, no clinical benefit of afatinib was observed in KRAS mutated patients in this phase II study. This evidence concerns the gene KRAS and colorectal carcinoma.